Indegene Limited share price
NSE: INDGN · ISIN INE065X01017
Key numbers
- Market cap
- ₹ 14,664 Cr
- Current price
- ₹ 608.95
- 52-week high / low
- ₹ 622 / 414
- Stock P/E
- 35.7
- Book value
- ₹ 130.3
- Dividend yield
- 0.37%
- ROCE
- 18.0%
- ROE
- 13.9%
- Debt to equity
- 0.05
- Sales growth (3 yrs)
- 15.0%
- Profit growth (3 yrs)
- 14.7%
- 1-year return
- 6.4%
About Indegene Limited
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 756 | 761 | 942 | 1,003 | 1,063 |
| Operating profit | 148 | 155 | 160 | 164 | 174 |
| Net profit | 118 | 116 | 103 | 80 | 116 |
| EPS (₹) | 4.91 | 4.86 | 4.29 | 3.32 | 4.84 |
Concall summary (2026-08-06)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- First, I will refer to our August 2025 earnings call in which we highlighted investments in go-to-market and technology, impacting margins by 150 basis points starting Q3 of FY26 with a 6 to 8 quarter period for normalization.
- Indegene Limited July 31, 2026 Through the inflection point in Q3 FY27, the EBITDA in H2 FY27 will be back in the range that we have operated in the past, that is 19% to 20%.
Growth & demand
- Notably, the top 20 global pharma companies who are the core o f our customer base are outpacing that average with cumulative revenue growth of roughly 10% to 12% year-on-year in the first calendar quarter.
- But an uptick in partnerships and M&A provided relief with big pharma spending over $100 billion on biopharma acquisitions in the first half - on pace for the largest deal value since 2019 - as companies buy pipeline to address patent cliffs .
Margins & costs
- Our EBITDA for the quarter was INR1,795 million at a margin of 16.9%.
- First, we have invested in workforce transformation that had a onetime impact on margins this quarter but will have a long-term impact in reducing our employee cost as well as tempering the impact of wage hikes going forward.
Capex & expansion
- Now in this period, we prioritized gaining market share and continue to build on our competitive differentiators by building proprietary Gen AI platforms, investing in G TM and making strategic acquisitions.
- If I take a slightly long-term view, we continue to invest in our capabilities and tech stack, building end -to-end solutions for our clients to adopt AI much more meaningfully .
Balance sheet & cash
- And what specific measures are being taken to manage margins, cash flow and strengthen the balan ce sheet, especially in areas like client receivables compliance or currency volatility.
- Coming back to the risks on receivables and cash flow management.
Peers in Health Information Services
Data for information only, not investment advice. Prices end of day.